Meldonium Overview, Dosing & Safety | Peptide Database

Meldonium (Mildronate)

Metabolic Modulator | Endurance & Cardioprotection

Community Research

Join others researching Meldonium — share findings, ask questions, and learn from real experiences

Meldonium (marketed as Mildronate) is a cardioprotective and anti-ischemic drug developed at the Latvian Institute of Organic Synthesis in the 1970s by Ivars Kalvins. It is approved and widely prescribed in Latvia, Lithuania, Russia, and several other post-Soviet states for the treatment of coronary artery disease, heart failure, and cerebrovascular conditions. Meldonium has never been approved by the FDA or EMA, and it remains unavailable through conventional pharmaceutical channels in the United States and most of Western Europe. The drug gained worldwide notoriety in March 2016 when tennis star Maria Sharapova announced she had tested positive for meldonium after the World Anti-Doping Agency (WADA) added it to the Prohibited List effective January 1, 2016. Her positive test was far from isolated -- WADA reported that meldonium was the most common substance detected in doping control samples in early 2016, with hundreds of athletes across multiple sports testing positive, predominantly from Eastern European and Central Asian countries. This widespread use reflected meldonium's longstanding popularity among athletes in those regions, where it was both legally available by prescription and culturally accepted as a general-purpose cardioprotective and performance-enhancing agent. In the performance enhancement community, meldonium has attracted particular interest among anabolic steroid users seeking cardiac protection during cycles, given the well-documented cardiotoxic effects of supraphysiological androgen use including left ventricular hypertrophy, impaired diastolic function, and accelerated atherosclerosis.

Meldonium exerts its primary pharmacological effect by inhibiting gamma-butyrobetaine hydroxylase (BBOX), the enzyme responsible for the final step in the biosynthesis of L-carnitine from gamma-butyrobetaine (GBB). By competitively blocking this enzyme, meldonium reduces endogenous carnitine production, which in turn lowers intracellular carnitine concentrations over time. Since carnitine is essential for the transport of long-chain fatty acids across the inner mitochondrial membrane via the carnitine palmitoyltransferase (CPT) system, reduced carnitine levels impair fatty acid beta-oxidation. This forces cells -- particularly cardiomyocytes and skeletal muscle cells -- to shift their metabolic fuel preference from fatty acid oxidation toward glucose oxidation. This metabolic shift is the cornerstone of meldonium's cardioprotective mechanism. Under ischemic conditions (reduced blood flow), fatty acid oxidation becomes metabolically inefficient and even harmful: incomplete fatty acid oxidation generates toxic intermediates (long-chain acylcarnitines and acyl-CoA species) that damage cell membranes and impair mitochondrial function. Glucose oxidation, by contrast, requires less oxygen per molecule of ATP produced and does not generate these toxic intermediates. By forcing the heart to rely more on glucose, meldonium effectively optimizes energy production under oxygen-limited conditions and reduces the accumulation of cardiotoxic lipid metabolites. Additionally, the accumulation of GBB that results from BBOX inhibition has been shown to stimulate nitric oxide (NO) production via an ester-mediated mechanism, promoting vasodilation, improving endothelial function, and reducing peripheral vascular resistance. Meldonium also upregulates the expression of glucose transporter proteins (GLUT-1 and GLUT-4) and activates components of the Akt-dependent cardioprotective signaling pathway, further enhancing myocardial resistance to ischemic injury.

Molecular Data

Research Indications

Meldonium is increasingly used in the performance enhancement community as an adjunctive agent to protect the heart during anabolic steroid cycles. Supraphysiological androgen use is associated with left ventricular hypertrophy, impaired diastolic function, reduced ejection fraction, and accelerated atherosclerosis. Meldonium's ability to optimize cardiac energy metabolism and reduce toxic lipid intermediates may mitigate some of these effects, though direct clinical evidence in this specific context is limited to anecdotal and observational data.

By shifting fuel utilization from fatty acids toward glucose, meldonium may improve aerobic efficiency under submaximal exercise conditions. Athletes in Eastern European countries have used meldonium for decades to support training capacity and recovery. The metabolic shift may spare glycogen during prolonged activity and reduce post-exercise oxidative stress. This use drove WADA's decision to ban the substance.

In Baltic states and Russia, meldonium is an approved prescription drug for the treatment of stable angina pectoris and chronic ischemic heart disease. Clinical trials conducted primarily in Latvia and Russia have demonstrated reductions in angina frequency, improved exercise tolerance on treadmill testing, and reduced nitroglycerin consumption when meldonium is added to standard antianginal therapy.

Meldonium has been investigated as an adjunctive therapy in chronic heart failure, where impaired cardiac energy metabolism contributes to disease progression. Small trials have reported improvements in exercise capacity and quality-of-life scores when meldonium was added to standard heart failure regimens. Larger-scale, Western-standard randomized controlled trials are lacking.

The drug is prescribed in some Eastern European countries for acute and chronic cerebrovascular insufficiency. Its vasodilatory effects via nitric oxide stimulation and metabolic optimization may offer neuroprotective benefits during ischemic events. Evidence is primarily from non-Western clinical trials.

Dosing Protocols

Meldonium is primarily administered orally in capsule form. Standard pharmaceutical preparations (Mildronate) are available as 250 mg and 500 mg capsules. The drug has good oral bioavailability and reaches peak plasma concentrations within 1-2 hours of ingestion. Its relatively short half-life of 4-6 hours means some protocols split the daily dose into two administrations, though once-daily dosing is also common. An intravenous formulation exists and is used in clinical settings for acute cardiac events, but oral administration is the standard route for all performance enhancement and chronic use applications.

Cardioprotection (On-Cycle Support)

500 mg/day

Once daily or split into two doses (250 mg twice daily)

Oral (capsule)

Clinical Dose (Ischemic Heart Disease)

500-1000 mg/day

Once daily or split into two doses

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Mild gastrointestinal discomfort (nausea, dyspepsia, or stomach upset -- typically transient and dose-dependent)

Occasional heartburn or acid reflux, especially at higher doses or when taken on an empty stomach

Stop Signs - Discontinue if:

Signs of allergic reaction: rash, urticaria, swelling, difficulty breathing

Severe or persistent gastrointestinal symptoms that do not resolve with dose adjustment

Significant tachycardia or cardiac arrhythmia

Unexplained muscle weakness or fatigue (may indicate excessive carnitine depletion)

Contraindications

Known hypersensitivity to meldonium or any excipients

Pregnancy or breastfeeding (insufficient safety data)

Individuals under 18 years of age

Severe hepatic or renal impairment (limited pharmacokinetic data in these populations)

Increased intracranial pressure (listed as a contraindication in some regional prescribing information)

Quality Checklist

Good Signs

Pharmaceutical-grade Mildronate capsules manufactured by Grindeks (the original Latvian pharmaceutical company)

Clearly labeled with compound name, dose per capsule (250 mg or 500 mg), batch number, and expiration date

Intact blister packaging with no signs of tampering or moisture damage

Sourced from a licensed pharmacy in a country where the drug is approved (Latvia, Lithuania, Russia, etc.)

Third-party lab testing confirms identity and potency if purchased from a non-pharmacy source

Warning Signs

Loose capsules or tablets not in original pharmaceutical packaging

No batch number or expiration date visible

Purchased from an unverified online supplier without reputation or reviews

Priced significantly below the typical cost of genuine Grindeks-manufactured product

Labeled as a research chemical or supplement rather than a pharmaceutical product

Bad Signs

Capsules show discoloration, unusual odor, or signs of degradation

No labeling, incorrect labeling, or packaging in a language inconsistent with claimed country of origin

Third-party testing reveals wrong compound, significant underdosing, or contamination

Supplier has no verifiable reputation or has been flagged for selling counterfeit pharmaceuticals

Product arrives with broken seals, damaged packaging, or evidence of repackaging

Frequently Asked Questions

How does meldonium compare to L-carnitine for on-cycle cardioprotection?

They work through opposite mechanisms—meldonium inhibits carnitine synthesis to shift metabolism toward glucose, while L-carnitine enhances fatty acid oxidation. For steroid-induced cardiotoxicity, meldonium is superior because the metabolic shift reduces toxic lipid intermediates under ischemic stress. Don't use both together; they directly counteract each other. Meldonium is the better choice for acute cardiac protection during high-dose androgen cycles.

Can I use meldonium continuously, or do I need to cycle off?

Cycling meldonium is recommended: 4-6 weeks on, 2-4 weeks off. Prolonged use without breaks can cause excessive carnitine depletion, impairing fatty acid metabolism when you need it (fasting, endurance work). The cardioprotective benefits are sustained during the on-period, but cyclical use preserves your metabolic flexibility and prevents the mild fatigue some users report with continuous dosing.

Is meldonium banned by WADA, and will it show on a drug test?

Yes, meldonium was banned by WADA in January 2016 and is prohibited in-competition. It's detectable in urine for 24-48 hours after the final dose. If you're subject to anti-doping testing (competitive sports, military, law enforcement), meldonium is off-limits. In non-tested contexts, it remains a useful on-cycle cardioprotective adjunct.

What's the optimal timing—run meldonium throughout a cycle or only during peak dose phases?

Running it during the entire cycle provides consistent cardioprotection, but many users run it only during the middle-to-final phases (weeks 6-12 of a 16-week cycle) when androgen-induced cardiac stress peaks. This approach preserves metabolic flexibility early on when carnitine is needed for training capacity, then shifts to cardioprotection when androgenic load is highest.

References

Comprehensive review of meldonium's mechanism of action and clinical applications. Confirmed that meldonium inhibits carnitine biosynthesis and transport, shifting cellular energy metabolism from fatty acid oxidation to glucose oxidation. Summarized evidence supporting its use in ischemic heart disease and cerebrovascular conditions.

Demonstrated that meldonium reduced myocardial infarct size in a rat model of ischemia-reperfusion injury without significant hemodynamic effects. Supported the hypothesis that metabolic modulation via carnitine pathway inhibition provides direct cardioprotection independent of changes in blood pressure or heart rate.

Randomized controlled trial showing that meldonium at 1000 mg/day improved exercise tolerance and quality of life in patients with chronic heart failure compared to placebo. The study supported meldonium as an adjunctive therapy for heart failure management.

Published in response to the WADA ban and the Sharapova case, this review summarized meldonium's pharmacology, clinical evidence, and the rationale for its prohibition in sport. Noted the discrepancy between meldonium's widespread use in Eastern Europe and the lack of large-scale Western clinical trials, and discussed the challenges of establishing performance-enhancing effects definitively.

Related Peptides

Telmisartan (an angiotensin II receptor blocker with PPAR-gamma agonist activity) and meldonium offer complementary mechanisms for cardiac protection. Telmisartan provides afterload reduction, anti-inflammatory effects, and metabolic benefits via PPAR-gamma activation, while meldonium optimizes cardiac energy metabolism and reduces ischemic damage. The combination is particularly relevant for steroid users seeking comprehensive cardiovascular protection, as telmisartan also addresses blood pressure elevation common with androgen use.

Meldonium does not interfere with androgen receptor signaling, testosterone metabolism, or the hypothalamic-pituitary-gonadal axis. It is commonly used alongside exogenous testosterone specifically to provide cardioprotective support against androgen-induced cardiac remodeling. Meldonium does not affect testosterone's anabolic efficacy and is considered a complementary adjunct.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.